PDE4A

(redirected from PDE4)

PDE4A

A gene on chromosome 19p13.2 that encodes a cyclic nucleotide phosphodiesterase, which plays a critical role in signal transduction, regulating intracellular cyclic nucleotide concentrations by hydrolysing the second messenger cAMP to AMP, thereby having a role in regulating physiological processes.
References in periodicals archive ?
PDE4 inhibition results in increased intracellular cAMP levels, which is thought to indirectly modulate the production of inflammatory mediators.
MM36 review: selective inhibition of PDE4 subtype B is effective in the topical treatment of atopic dermatitis.
Treatment in atopic dermatitis often begins with non-pharmacologic measures and progresses to the use of topical corticosteroids, topical calcineurin inhibitors and topical PDE4 inhibitors.
BFBO concentration-dependently inhibited the cyclic GMP-hydrolyzing activity of basal PDE1, calmodulin-activated PDE1 and PDE5, and of cyclic AMP-hydrolyzing activity of PDE3 and PDE4 with [IC.
Anacor's flagship asset, crisaborole, a differentiated non-steroidal topical PDE4 inhibitor with anti-inflammatory properties, is currently under review by the US FDA for the treatment of mild-to-moderate atopic dermatitis, commonly referred to as eczema.
Anacor's lead asset, crisaborole, is a non-steroidal topical PDE4 inhibitor with anti-inflammatory properties currently under review by the U.
Segmentation by mechanism of action and analysis of: TNF inhibitors, PDE4 inhibitors, & interleukin blockers
is the only oral PDE4 inhibitor, (a type of drug that has anti-inflammatory effects) approved for the treatment of COPD.
patent recently awarded to HG&H Pharmaceuticals protects the modulation of 5-HT and PDE4 and the application of mesembrenone as a PDE4 inhibitor.
sup][9] The PDE4 isozymes in mammals are encoded by four genes termed PDE4A-4D, and each gene has unique, nonredundant role in regulation of cell functions.
In addition, we compared the signaling events that are measured in wildtype to PDE4 isoform specific KO cells to determine the role of each PDE4 isoform in regulating localized cAMP signals in cells.
Upon completion of the transaction, AstraZeneca will own the development and commercial rights to Tudorza Pressair (aclidinium bromide inhalation powder), a twice-daily long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease (COPD), and Daliresp (roflumilast), a once-daily oral PDE4 inhibitor currently on the market for COPD.